Patents by Inventor Daniel F. Nogales

Daniel F. Nogales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azepine compounds
    Patent number: 5708168
    Abstract: Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.
    Type: Grant
    Filed: October 17, 1995
    Date of Patent: January 13, 1998
    Assignees: State of Oregon, Acting by and through The Oregon State Board of Higher Education, Acting for and on behalf of The Oregon Health Sciences University and The University of Oregon, Eugene Oregon, ACEA Pharmaceuticals, Inc.
    Inventors: John F. W. Keana, Anthony P. Guzikowski, Daniel F. Nogales, Sui Xiong Cai
  • Azepine synthesis via a diels-alder reaction
    Patent number: 5476933
    Abstract: Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: December 19, 1995
    Assignees: State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon health Sciences University and The University of Oregon, Acea Pharmaceuticals, Inc.
    Inventors: John F. W. Keana, Anthony P. Guzikowski, Daniel F. Nogales, Sui X. Cai